← Back to Search

Alkylating agents

Intent-to-Treat for Myelomonocytic Leukemia

Phase 1 & 2
Waitlist Available
Led By Margaret MacMillan, MD
Research Sponsored by Masonic Cancer Center, University of Minnesota
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 1 year after transplant
Awards & highlights

Study Summary

This trial is testing if a certain combination of cancer drugs followed by a stem cell transplant can help people with a certain type of blood cancer achieve long-term disease-free survival.

Eligible Conditions
  • Myelomonocytic Leukemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 1 year after transplant
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 1 year after transplant for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Determine Probability of Long-term Disease Free Survival in JMML
Secondary outcome measures
Combined Incidence of Neutrophil Engraftment, Graft-versus-host Disease (GVHD), Regimen-related Toxicity, and Relapse.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Intent-to-TreatExperimental Treatment2 Interventions
Patients receiving study regimen.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Stem Cell Transplant
2007
Completed Phase 3
~1350
Preparative Regimen
1999
Completed Phase 2
~80

Find a Location

Who is running the clinical trial?

Masonic Cancer Center, University of MinnesotaLead Sponsor
271 Previous Clinical Trials
14,610 Total Patients Enrolled
Margaret MacMillan, MDPrincipal InvestigatorMasonic Cancer Center, University of Minnesota
5 Previous Clinical Trials
97 Total Patients Enrolled

Media Library

Preparative Regimen (Alkylating agents) Clinical Trial Eligibility Overview. Trial Name: NCT00167219 — Phase 1 & 2
Myelomonocytic Leukemia Research Study Groups: Intent-to-Treat
Myelomonocytic Leukemia Clinical Trial 2023: Preparative Regimen Highlights & Side Effects. Trial Name: NCT00167219 — Phase 1 & 2
Preparative Regimen (Alkylating agents) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00167219 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)
1999. "Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00167219.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top